Heart and Blood Diseases

All Conditions

Digestive System Diseases

Blood and Lymph Conditions

Neoplasms

Nervous System Diseases

Symptoms and General Pathology

Rare Diseases

Hypertension

Hypertension, Portal

Myeloproliferative Disorders

Varicose Veins

Hemangioma, Cavernous

Hemangioma

Esophageal and Gastric Varices

Vascular Diseases

Bone Marrow Diseases

Hematologic Diseases

Liver Diseases

Gastrointestinal Diseases

Esophageal Diseases

Neoplasms, Vascular Tissue

Neoplasms by Histologic Type

Syndrome

Brain Diseases

Central Nervous System Diseases

Hemostatic Disorders

Blood Coagulation Disorders

Hemorrhagic Disorders

Chronic Myeloproliferative Disorders

Patients with portal caver cavernoma and gastroesophageal varices and JAK2 Mutation.

Patients with portal caver cavernoma and gastroesophageal varices without JAK2 Mutation.

Patients with portal caver cavernoma will be divided into two groups by the result of JAK2 mutation test

JAK2 mutation test

Xiaoquan HUANG, M.D.

Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. Portal vein thrombosis and portal cavernoma frequently occur in the MPN population and the management of gastroesophageal varices in these patients are sometimes technically difficult. The aim of this study is to investigate the the characteristics of patients with gastroesophageal varices and portal caver cavernoma with or without JAK2 mutation.

Gastroesophageal Varices in Cavernoma

Characteristic of Patients With Gastroesophageal Varices and Portal Cavernoma

Have a history of the occurrence of gastroesophageal variceal bleeding

The concurrence of complications of portal hypertension (ascites, infections, variceal bleeding, et al)

Shanghai Zhongshan Hospital

Resident

Fibrinolytic Agents

Anticoagulants

All Drugs and Chemicals

Heparin

Warfarin

Rivaroxaban

Calcium heparin

Heparin, Low-Molecular-Weight

Tinzaparin

Dalteparin

Patients with JAK2 mutation and gastroesophageal varices receive anticoagulation agents.

Patients with JAK2 mutation and gastroesophageal varices who didn't receive anticoagulation agents.

Patients receive anticoagulation agents including low molecular weight heparin, warfarin, rivaroxaban, et al.

Anticoagulation Agents

Xiaoquan HUANG, Ph.D

Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. The aim of this study is to evaluate the efficacy of anticoagulation in patients with JAK2 mutation and gastroesophageal varices.

Anticoagulation in Gastroesophageal Varices and JAK2 Mutation

Anticoagulation Treatment of Patients With Gastroesophageal Varices and JAK2 V617 Mutation

The changes of portal vein thrombosis including progression, disappear or unchanged.

The occurrence of variceal bleeding including haematemesis and melena

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Gastroesophageal Varices in Cavernoma	NCT04525768	Gastroesophagea... Myeloproliferat... Portal Caver Ca... Portal Hyperten...	JAK2 mutation t...	18 Years - 75 Years	Shanghai Zhongshan Hospital
Anticoagulation in Gastroesophageal Varices and JAK2 Mutation	NCT04527666	Gastroesophagea... JAK2 Mutation Myeloproliferat...	Anticoagulation...	18 Years - 75 Years	Shanghai Zhongshan Hospital

Spots Global Cancer Trial Database for gastroesophageal varices